Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6465MR)

This product GTTS-WQ6465MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6465MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1604MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ353MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14957MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ9451MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ3429MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ10361MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ13949MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW